Latest Granisetron Stories
CALIFON, NJ, July 6, 2011 /PRNewswire/ - PediatRx, Inc.
LONDON, June 8, 2011 /PRNewswire/ -- - New data presented at the European Hematology Association (EHA) 2011 Annual Meeting in London show better control of nausea and vomiting with the combination palonosetron plus aprepitant when compared to granisetron in patients receiving multiday highly emetogenic conditioning chemotherapy regimens - Significantly higher the complete response during the acute, delayed and overall periods The combination of palonosetron (0.25 mg iv every 48 h)...
GRANISOL's co-pay program covers patient out-of-pocket costs for non-Medicare and non-Medicaid patients CALIFON, NJ, June 1, 2011 /PRNewswire/ - PediatRx, Inc.
Oncologists report that patient out-of-pocket costs can impact form of dosage CALIFON, NJ, May 5 /PRNewswire/ - PediatRx, Inc.
Fear of nausea a significant issue and often not discussed with healthcare providers CALIFON, NJ, April 25 /PRNewswire/ - PediatRx, Inc.
CALIFON, N.J., April 13, 2011 /PRNewswire/ -- PediatRx, Inc. (OTCBB: PEDX) announced that the U.S. Centers for Medicare and Medicaid Services (CMS) recently notified state Medicaid agencies to include PediatRx's GRANISOL, NDC 52547-0801-30, in their list of reimbursed products.
Patients could instantly save up to $200 off the cost of their co-pay CALIFON, NJ, Feb. 1 /PRNewswire/ - PediatRx Inc.
- To give a box on the ear to.